What is Acadia Pharmaceuticals's SG&A?

Acadia Pharmaceuticals (ACAD) reported SG&A of $171.02M in Q1 2026.

How has Acadia Pharmaceuticals's SG&A changed year-over-year?

Acadia Pharmaceuticals's SG&A increased by 35.3% year-over-year, from $126.37M to $171.02M.

What is the long-term trend for Acadia Pharmaceuticals's SG&A?

Over 4 years (2021 to 2025), Acadia Pharmaceuticals's SG&A has grown at a 8.5% compound annual growth rate (CAGR), from $396.03M to $548.89M.

Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.

Acadia Pharmaceuticals ACAD SG&A

SG&A at other companies

BiogenBIIB

$607.3M+6.1%

Neurocrine BiosciencesNBIX

$318.5M+15.2%

Catalyst PharmaceuticalCPRX

$49.32M+5.1%

PTC TherapeuticsPTCT

$86.18M+6.5%

BridgeBio PharmaBBIO

$163.9M+54.1%

TG TherapeuticsTGTX

$88.22M+75.3%

Segments

By segment

See full

Reportable Segment Aggregation Before Other Operating$171.02M+35.3%

Other financials

Income statement

See full

Revenue$268.1M+9.7%

Gross profit$243.3M+8.6%

Operating income-$4.6M-124%

Net income$3.6M-80.8%

EPS (diluted)$0.02-81.8%

Balance sheet

See full

Cash & equivalents$282.2M+29.6%

Total debt$50.8M-9.3%

Total equity$1.2B+63.1%

Total assets$1.6B+41.8%

Cash flow

See full

Operating cash flow$34.0M+67.2%

CapEx$5.2M—

Free cash flow$28.8M+41.6%

Valuation

See full

Market cap$3.7B+37.0%

Enterprise value$3.47B+36.6%

P/E9.9×-2.0×

P/S3.4×+0.7×

Profitability

See full

Gross margin91.5%-0.6pp

Operating margin7.4%-16.2pp

Net margin34.3%+11.3pp

FCF margin18.9%—

Returns & leverage

See full

Return on equity37.3%+0.1pp

Debt / equity0×0.0×

Current ratio3.6×+0.7×

Where this comes from

Reported directly by Acadia Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.

The official record: Acadia Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Acadia Pharmaceuticals's sg&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Acadia Pharmaceuticals's SG&A?: Acadia Pharmaceuticals (ACAD) reported SG&A of $171.02M in Q1 2026.
How has Acadia Pharmaceuticals's SG&A changed year-over-year?: Acadia Pharmaceuticals's SG&A increased by 35.3% year-over-year, from $126.37M to $171.02M.
What is the long-term trend for Acadia Pharmaceuticals's SG&A?: Over 4 years (2021 to 2025), Acadia Pharmaceuticals's SG&A has grown at a 8.5% compound annual growth rate (CAGR), from $396.03M to $548.89M.
What does SG&A mean?: Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.